Immunogenicity & Risk Management
Examine immune responses associated with biosimilars and other biologic therapies.Discuss anti-drug antibodies, neutralizing antibodies, and immunogenicity assessment.Explore advanced assay technologies and risk-management strategies.Highlight regulatory expectations for preclinical and clinical immunogenicity evaluation.Focus on approaches for improving safety and therapeutic outcomes.
Related Conference of Immunogenicity & Risk Management
December 01-02, 2026
21st World Congress on Biomarkers, Cancer Therapy & Clinical Research
Dubai, UAE
June 07-08, 2027
42nd International Conference on Next-Gen Biotechnology and Applications
Atlanta, USA
Immunogenicity & Risk Management Conference Speakers
Recommended Sessions
- AI in Biotherapeutics
- Biobetters & Novel Biologics
- Biosimilar Development
- Biosimilars in Oncology
- Cell & Gene Therapies
- Clinical Comparability
- Formulation & Drug Delivery
- Future Biotherapeutics
- Global Biosimilar Adoption
- Immunogenicity & Risk Management
- Interchangeability & Switching
- Manufacturing & Quality Control
- Market Access & Reimbursement
- Market Trends & Partnerships
- Monoclonal Antibodies
- Patient & Physician Perspectives
- Pharmacovigilance
- Rare Disease Biosimilars
- Real-World Evidence
- Regulatory Pathways
Related Journals
Are you interested in
- Advanced Biomanufacturing and Smart Bioprocess Engineering - Euro Biotechnology 2027 (France)
- Agricultural Biotechnology & Crop Improvement - Biotechnology- 2026 (Germany)
- AI in Biotherapeutics - Biosimilars 2027 (USA)
- AI-Driven Biotechnology and Digital Life Sciences - Euro Biotechnology 2027 (France)
- Analytical Techniques and Laboratory Methods - BIOMEDICINE 2026 (Italy)
- Antibiotic Discovery and Development - Euro Antibiotics 2027 (France)
- Antibiotics in Agriculture and Food Safety - Euro Antibiotics 2027 (France)
- Antimicrobial Peptides and Host Defense - Euro Antibiotics 2027 (France)
- Antimicrobial Resistance and Superbugs - Euro Antibiotics 2027 (France)
- Antimicrobial Stewardship - Euro Antibiotics 2027 (France)
- Artificial Intelligence in Drug Discovery and Pharmacotherapy - BIOMEDICINE 2026 (Italy)
- Bacterial Pathogenesis and Virulence - Euro Antibiotics 2027 (France)
- Biobetters & Novel Biologics - Biosimilars 2027 (USA)
- Biofilms and Chronic Bacterial Infections - Euro Antibiotics 2027 (France)
- Bioinformatics & Computational Biology - Biotechnology- 2026 (Germany)
- Bioinformatics and Biomarkers - Biomarkers 2026 (UAE)
- Biomarker Detection Technologies - Biomarkers 2026 (UAE)
- Biomarker Discovery and Precision Diagnostics - Euro Biotechnology 2027 (France)
- Biomarkers in Drug Development - Biomarkers 2026 (UAE)
- Biopharmaceutical Development - Biotechnology- 2026 (Germany)
- Biosensors, Wearable Biotechnology and Digital Health - Euro Biotechnology 2027 (France)
- Biosimilar Development - Biosimilars 2027 (USA)
- Biosimilars in Oncology - Biosimilars 2027 (USA)
- Biotechnology Entrepreneurship, Venture Capital and Innovation - Euro Biotechnology 2027 (France)
- Biotechnology for Rare and Genetic Diseases - Euro Biotechnology 2027 (France)
- Cardiovascular Pharmacotherapy - BIOMEDICINE 2026 (Italy)
- Cell & Gene Therapies - Biosimilars 2027 (USA)
- Cell and Gene Therapy Manufacturing - Euro Biotechnology 2027 (France)
- Clinical Comparability - Biosimilars 2027 (USA)
- Clinical Microbiology and Bacterial Diagnostics - Euro Antibiotics 2027 (France)
- Clinical Pharmacology and Therapeutics - BIOMEDICINE 2026 (Italy)
- Clinical Trials and Therapeutic Advances - Euro Antibiotics 2027 (France)
- Clinical Trials and Translational Research - BIOMEDICINE 2026 (Italy)
- CRISPR & Gene Therapy Applications - Biotechnology- 2026 (Germany)
- Drug Discovery and Development - BIOMEDICINE 2026 (Italy)
- Emerging and Re-Emerging Bacterial Infections - Euro Antibiotics 2027 (France)
- Emerging Technologies in Biotechnology - Euro Biotechnology 2027 (France)
- Emerging Therapies and Innovative Drugs - BIOMEDICINE 2026 (Italy)
- Environmental & Green Biotechnology - Biotechnology- 2026 (Germany)
- Environmental Biomarkers - Biomarkers 2026 (UAE)
- Epigenetic Biomarkers - Biomarkers 2026 (UAE)
- Ethics in Biomarker Research - Biomarkers 2026 (UAE)
- Formulation & Drug Delivery - Biosimilars 2027 (USA)
- Future Biotherapeutics - Biosimilars 2027 (USA)
- Future Trends in Biomarker Research - Biomarkers 2026 (UAE)
- Genetic Engineering & Genome Editing - Biotechnology- 2026 (Germany)
- Genome Engineering and Functional Genomics - Euro Biotechnology 2027 (France)
- Genomic Biomarkers - Biomarkers 2026 (UAE)
- Genomics, Proteomics and Molecular Epidemiology - Euro Antibiotics 2027 (France)
- Global Biosimilar Adoption - Biosimilars 2027 (USA)
- Global Biotechnology Collaboration and Future Innovation - Euro Biotechnology 2027 (France)
- Hospital-Acquired and Healthcare-Associated Infections - Euro Antibiotics 2027 (France)
- Immunobiology and Immunotherapy in Biomedicine - BIOMEDICINE 2026 (Italy)
- Immunoengineering and Advanced Therapeutics - Euro Biotechnology 2027 (France)
- Immunogenicity & Risk Management - Biosimilars 2027 (USA)
- Immunotherapy and Biologics - BIOMEDICINE 2026 (Italy)
- Industrial Biotechnology & Bioprocessing - Biotechnology- 2026 (Germany)
- Infectious Disease Biomarkers - Biomarkers 2026 (UAE)
- Interchangeability & Switching - Biosimilars 2027 (USA)
- Liquid Biopsies in Oncology - Biomarkers 2026 (UAE)
- Manufacturing & Quality Control - Biosimilars 2027 (USA)
- Market Access & Reimbursement - Biosimilars 2027 (USA)
- Market Trends & Partnerships - Biosimilars 2027 (USA)
- Microbial Biotechnology & Fermentation - Biotechnology- 2026 (Germany)
- Microbiome and Bacterial Infection - Euro Antibiotics 2027 (France)
- Microbiome Engineering and Microbial Therapeutics - Euro Biotechnology 2027 (France)
- Molecular Diagnostics & Biomarkers - Biotechnology- 2026 (Germany)
- Molecular Diagnostics and Biomarker Discovery - BIOMEDICINE 2026 (Italy)
- Molecular Medicine and Genetics - BIOMEDICINE 2026 (Italy)
- Monitoring Chronic Disease with Biomarkers - Biomarkers 2026 (UAE)
- Monoclonal Antibodies - Biosimilars 2027 (USA)
- Multi-Omics and Systems Biotechnology - Euro Biotechnology 2027 (France)
- Nanobiotechnology & Drug Delivery - Biotechnology- 2026 (Germany)
- Nanobiotechnology in Biomedicine - BIOMEDICINE 2026 (Italy)
- Nanomedicine and Drug Delivery Systems - BIOMEDICINE 2026 (Italy)
- Nanotechnology and Advanced Antibacterial Strategies - Euro Antibiotics 2027 (France)
- Nanotechnology Applications in Pharmacotherapy - BIOMEDICINE 2026 (Italy)
- Natural Products and Phytopharmacology - BIOMEDICINE 2026 (Italy)
- Neuropharmacology and Central Nervous System Therapies - BIOMEDICINE 2026 (Italy)
- Novel Antimicrobial Therapies - Euro Antibiotics 2027 (France)
- Oncology Pharmacotherapy - BIOMEDICINE 2026 (Italy)
- One Health and Antimicrobial Resistance - Euro Antibiotics 2027 (France)
- Organoids, Organ-on-Chip and Advanced Disease Models - Euro Biotechnology 2027 (France)
- Patient & Physician Perspectives - Biosimilars 2027 (USA)
- Pediatric and Geriatric Bacterial Infections - Euro Antibiotics 2027 (France)
- Pediatric and Geriatric Pharmacotherapy - BIOMEDICINE 2026 (Italy)
- Pediatric Biomarkers - Biomarkers 2026 (UAE)
- Personalized & Precision Medicine - Biotechnology- 2026 (Germany)
- Pharmacogenomics and Personalized Medicine - BIOMEDICINE 2026 (Italy)
- Pharmacovigilance - Biosimilars 2027 (USA)
- Pharmacovigilance and Drug Regulation - BIOMEDICINE 2026 (Italy)
- Protein Engineering and Computational Protein Design - Euro Biotechnology 2027 (France)
- Proteomics in Biomarker Discovery - Biomarkers 2026 (UAE)
- Psychiatric Biomarkers - Biomarkers 2026 (UAE)
- Public Health, Policy and Global AMR Strategies - Euro Antibiotics 2027 (France)
- Public Health, Policy and Global AMR Strategies - Euro Antibiotics 2027 (France)
- Rare Disease Biosimilars - Biosimilars 2027 (USA)
- Real-World Evidence - Biosimilars 2027 (USA)
- Regenerative Medicine and Cell Therapy - BIOMEDICINE 2026 (Italy)
- Regulatory Pathways - Biosimilars 2027 (USA)
- Regulatory Science, Quality Systems and Global Compliance - Euro Biotechnology 2027 (France)
- RNA Biology and Next-Generation RNA Therapeutics - Euro Biotechnology 2027 (France)
- Sepsis and Severe Bacterial Infections - Euro Antibiotics 2027 (France)
- Stem Cell Innovations - Biotechnology- 2026 (Germany)
- Stem Cell Therapy and Regenerative Biomedicine - BIOMEDICINE 2026 (Italy)
- Sustainable Biotechnology and Circular Bioeconomy - Euro Biotechnology 2027 (France)
- Synthetic & Systems Biology - Biotechnology- 2026 (Germany)
- Synthetic Cells and Cell-Free Biotechnology - Euro Biotechnology 2027 (France)
- Systems Pharmacology and Computational Biology - BIOMEDICINE 2026 (Italy)
- Tissue Engineering & Regenerative Medicine - Biotechnology- 2026 (Germany)
- Toxicology and Safety Assessment - BIOMEDICINE 2026 (Italy)
- Translational Biomarker Research - Biomarkers 2026 (UAE)
- Translational Biotechnology & Commercialization - Biotechnology- 2026 (Germany)
- Translational Biotechnology and Clinical Innovation - Euro Biotechnology 2027 (France)
- Vaccines Against Bacterial Infections - Euro Antibiotics 2027 (France)